Terns Pharmaceuticals is planning to stop investing in metabolic disease clinical development at the end of 2025, starting a countdown to potential deals for assets including a midphase oral obesity ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

The Department of Health and Human Services has announced a plan to end mRNA vaccine work funded by the Biomedical Advanced ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Alcon is building out its portfolio of lens implants, with a $1.5 billion deal to acquire the flagging Staar Surgical and its ...

A phase 2b trial of HMNC Brain Health’s depression drug candidate has missed its primary endpoint. But while the ex-Sanofi molecule failed to move the needle in the overrall population, results in ...

Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...